Meanwhile, PD-1 inhibitors have been increasingly explored as representative agents for immunotherapy, the possible mechanism underlying the benefit of TACE combined with a PD-1 inhibitor was revealed: TACE could decrease the ratio of CD4+/CD8+ cells and increase the level of PD-1 mRNA expression in patients with HCC (12). This evidence concerns the gene CD8A and hepatocellular carcinoma.